Portable Ultrasound Maker Echoes 70% Higher on Compliance Win

A fast-food giant is losing its sizzle as its U.S. sales slide, an automobile giant is slashing its profit outlook due to mounting tariff pressures, and a portable ultrasound startup is soaring 65% after securing a crucial listing compliance win. Here’s what you need to know.

Crypto Uplist Watch (Sponsored)

This Quiet Crypto Player Is About to Make Noise

While most crypto stocks chase hype, this one delivers real results—$144 million in revenue and over $80 million in EBITDA last year.

Now, it’s filed a Form 40 with the SEC, setting the stage for a potential uplisting.

May 1st could change everything.

A profitable Bitcoin infrastructure company—still trading under the radar—may finally step into the spotlight.

Get the full story before the rest of the market catches up.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

Economic Reports:

Esports Market Watch (Sponsored)

The Future of Sports is Going Digital

This fast-moving digital media company—backed by the Dallas Cowboys’ owner—just acquired one of the most iconic gaming brands on the planet.

With projected revenues topping $100M and clients like Nestlé and GM, it’s building a next-gen platform that connects global brands to the hardest-to-reach audiences in Gen Z and Gen Alpha.

Their acquisition of a top-tier esports brand could be the turning point in the battle for youth attention.

Click here to see why this company could be the “Dallas Cowboys of Esports.”

Fast Food

Weak First-Quarter Results Weigh on McDonald’s Shares

McDonald’s (NYSE: MCD) stock is down in premarket trade today following a disappointing quarterly earnings release that revealed weaker-than-expected revenue and same-store sales.

The fast-food chain posted adjusted earnings of $2.67 per share, in line with expectations.

However, its revenue is down 3% year-over-year to $5.96 billion—falling short of the $6.12 billion analysts had anticipated.

Comparable sales globally declined by 1%, missing the modest 0.31% growth forecasted. The company noted sales were mostly unchanged when adjusting for last year's Leap Day.

In the U.S. market, however, comparable sales slid 3.6%, underperforming the 1.37% drop expected by Wall Street.

The stock is down 1.2% in premarket trading following the results. Despite the setback, McDonald’s has climbed 10% year-to-date.

Last quarter marked a brief rebound in global same-store sales after two periods of decline, but domestic figures continued to struggle—still feeling the effects of reduced customer traffic linked to a foodborne illness incident last October.

The report casts fresh doubt on the company’s momentum in its core U.S. market heading into the rest of 2025.

Automobiles

GM Revises Profit Forecast, Citing Up to $5 Billion in Trade Costs Due to Tariffs

General Motors (NYSE: GM) trimmed its 2025 profit outlook today, citing financial strain from recent tariff changes that could cost the company as much as $5 billion.

The updated guidance came shortly after the automaker withdrew a previous forecast that didn’t account for the latest trade policy shifts.

In a message to shareholders, CEO Mary Barra said the company remains in close communication with the White House and global trade partners as negotiations continue to evolve.

GM now expects its full-year adjusted operating income to fall between $10 billion and $12.5 billion. That’s a notable cut from its earlier range of $13.7 billion to $15.7 billion.

The estimated net income for the year was also lowered to between $8.2 billion and $10.1 billion, down from $11.2 billion to $12.5 billion.

The tariff-related impact alone is projected to range between $4 billion and $5 billion.

This revision comes amid broader uncertainty surrounding U.S. trade policy under the Trump administration and its implications for the automotive industry.

Shares of GM are down 3.6% on Thursday following the announcement.

Energy Sector Watch (Sponsored)

On Behalf of Azincourt Energy Corp

The Next Big Name in Uranium?

The uranium bull market is heating up.

Uranium has doubled since 2020.

Saskatchewan’s uranium sales just hit $2.6 billion, up 62% year-over-year.

Cameco says the long-term outlook has never been stronger.

Now layer on the global demand curve:

The setup is here.

And one company has plans to drill in the heart of it all: Canada’s Athabasca Basin.

With early uranium hits, expanding alteration zones, and proximity to NexGen and Cameco, this could be the next name to watch in the sector.

Discover the full story behind this quietly rising stock.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Pharmaceuticals

Eli Lilly Trims Outlook After Zepbound Sales Disappoint

Eli Lilly (NYSE: LLY) is seeing its stock drop 4.33% in premarket trading today after revenue from its high-profile weight-loss drug Zepbound slightly missed forecasts, despite an otherwise strong quarterly performance.

Zepbound brought in $2.31 billion in sales for the first quarter, narrowly missing analyst expectations of $2.33 billion, according to LSEG data.

The pharmaceutical company attributed the shortfall to recent price reductions, even as demand remained solid.

In February, the company lowered the monthly price of its lowest Zepbound doses to $349 and $499 while expanding dose availability online.

Adding to the pressure, CVS Health announced it would no longer list Zepbound as a preferred treatment for insurance reimbursement starting July 1, though it will continue covering competitor Novo Nordisk’s Wegovy.

Total revenue for the quarter reached $12.73 billion, slightly beating projections of $12.67 billion. Adjusted earnings landed at $3.34 per share, outpacing the $3.02 analysts had forecast.

Sales of diabetes treatment Mounjaro also exceeded expectations, totaling $3.84 billion versus the projected $3.80 billion.

Despite the solid earnings beat, Eli Lilly lowered its full-year adjusted profit guidance to a range of $20.78 to $22.28 per share, down from its earlier projection.

NanoVibronix, Inc. [NAOV] - Last Close: $2.86

NanoVibronix, Inc. is a medical device company specializing in noninvasive, portable ultrasound-based therapeutic devices. The company grew 12% in revenue last year while reducing net losses by 0.2%. ​

The stock is experiencing nearly 70% growth in premarket trading today after the company's recent announcement of regaining compliance with Nasdaq's listing requirements, alleviating delisting concerns and providing a stable foundation for future growth.​

Interactive Strength Inc. [TRNR] - Last Close: $0.65

Interactive Strength Inc. specializes in innovative specialty fitness equipment and digital fitness services under the CLMBR and FORME brands. In 2024, it reported a 459% year-over-year revenue increase to $5.4 million, while reducing net losses by 32% to $34.9 million. ​

The stock is experiencing a 21% uptick in premarket trading, due to the company's shareholder update confirming that its planned acquisitions are on track and reiterating 2025 pro forma revenue guidance of over $65 million. ​

Haverty Furniture Companies, Inc. [HVT] - Last Close: $18.16

Haverty Furniture is a U.S.-based retailer specializing in residential furniture. The firm has seen declining revenue and earnings, reflecting challenges in the housing market and consumer spending. Its stock is also down 19% YTD.

However, it is rising nearly 10% in premarket trade today after reporting a 58.33% growth in its Q1 net income, despite a drop in revenues.

Uranium Demand (Sponsored)

On Behalf of Azincourt Energy Corp

Why Uranium’s Next Cycle Could Be Bigger Than 2007

With AI pushing power demand through the roof, nuclear is the only option.

Uranium demand is set to double. One junior may benefit most.

Tap here to unlock the name.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club